ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DMRA vs NKTR // EV/EBITDA & P/E VALUATION

Damora Therapeutics Inc. (NASDAQ) VS. Nektar Therapeutics (NASDAQ) • 15-METRIC TALLY: DMRA 3 — NKTR 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DMRA VS. NKTR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DMRA NKTR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -0.49% -15.60% +15.11 DMRA /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -43.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.8 34.7 +15.10 DMRA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.36B $1.34B $21.1M DMRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DMRA REV NKTR REV DMRA GROSS % NKTR GROSS % DMRA FCF NKTR FCF
FY 2025 $0 $55.2M — 98.0% -$6.7M -$208.7M
FY 2024 $0 $98.4M — 68.8% -$18.6M -$177.2M
FY 2023 $0 $90.1M — — -$36.9M -$192.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DMRA // BETA —
NKTR // BETA —